A fludarabine-based conditioning regimen for severe aplastic anemia.

Area of Science:

• Hematology
• Immunology
• Transplantation Medicine

Background:

• Graft rejection is a significant challenge in alternative donor transplantation for severe aplastic anemia (SAA).
• Irradiation-based conditioning regimens improve engraftment but increase transplant-related complications, offering limited overall outcome improvement.
• Novel conditioning strategies are needed to enhance transplant success in SAA.

Purpose of the Study:

• To evaluate the efficacy and safety of a conditioning regimen combining fludarabine, cyclophosphamide, and anti-thymocyte globulin (ATG) for alternative donor transplantation in SAA patients.
• To assess engraftment rates, toxicity, and survival outcomes in SAA patients undergoing transplantation with this novel regimen.

Main Methods:

• A prospective study involving five multiply-transfused SAA patients.
• Conditioning regimen: fludarabine, cyclophosphamide, and ATG.
• Transplantation from HLA one-antigen disparate related donors (3 patients) or matched unrelated donors (2 patients).

Main Results:

• The conditioning regimen was well-tolerated, with only grade I toxicity observed.
• All five patients achieved complete donor chimerism.
• At a median follow-up of 9 months, all patients were alive and showed successful engraftment.

Conclusions:

• Fludarabine can effectively replace irradiation in conditioning regimens for alternative donor transplantation in SAA.
• The combination of fludarabine, cyclophosphamide, and ATG offers a safe and effective approach for SAA transplantation.
• This regimen enhances engraftment and survival outcomes in SAA patients.